MEDP
Medpace Holdings, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$652.01
−3.77%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.8B | 2.5B | 2.1B | 1.9B | 1.5B |
| Cost of Revenue | 2.0B | 1.8B | 1.5B | 1.4B | 1.0B |
| Gross Profit | 827.2M | 760.6M | 656.3M | 524.5M | 432.4M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 192.7M | 197.6M | 180.2M | 161.4M | 131.4M |
| General & Admin Expense | 51.8M | — | 178.7M | — | — |
| Selling & Marketing Expense | — | — | 1.5M | — | — |
| Other Expenses | 27.3M | 28.1M | 29.3M | 26.3M | 22.3M |
| Total Operating Expenses | 220.0M | 225.7M | 209.4M | 187.7M | 153.7M |
| Cost and Expenses | 2.2B | 2.0B | 1.7B | 1.5B | 1.2B |
| Operating Income (EBIT) | 607.1M | 534.9M | 446.9M | 336.8M | 278.7M |
| Non-Operating | |||||
| Interest Income | 5.3M | — | 25.0M | — | — |
| Interest Expense | — | — | — | 488.0K | 2.9M |
| Net Interest Income | 5.3M | — | 25.0M | (488.0K) | (2.9M) |
| Other Non-Op Income/Expense | 19.9M | 7.4M | 29.1M | (1.1M) | 4.2M |
| Non-Operating Income (excl Interest) | (8.9M) | (7.4M) | (29.1M) | 655.0K | (7.1M) |
| EBT (Pre-Tax Income) | 627.0M | 542.4M | 475.9M | 335.7M | 282.9M |
| Income Tax Expense | 109.2M | 91.3M | 71.5M | 52.9M | 37.5M |
| Bottom Line | |||||
| Net Income | 517.8M | 451.1M | 404.4M | 282.8M | 245.4M |
| Earnings from Cont. Ops | 517.8M | 451.1M | 404.4M | 282.8M | 245.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 517.8M | 451.1M | 404.3M | 282.6M | 245.2M |
| Per Share | |||||
| Basic EPS | $18.36 | $15.64 | $13.06 | $9.20 | $7.57 |
| Diluted EPS | $18.04 | $15.28 | $12.63 | $8.88 | $7.28 |
| Revenue Per Share | $101.59 | $87.72 | $68.13 | $61.38 | $45.08 |
| Shares | |||||
| Basic Shares Outstanding | 27.9M | 28.8M | 31.0M | 30.7M | 32.4M |
| Diluted Shares Outstanding | 28.4M | 29.5M | 32.0M | 31.8M | 33.7M |
| Profitability Metrics | |||||
| EBITDA | 643.5M | 570.5M | 505.2M | 362.5M | 308.1M |
| D&A | 27.5M | 28.1M | 29.3M | 26.3M | 22.3M |
| EBIT | 616.1M | 542.4M | 475.9M | 336.2M | 285.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026